Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18867933 | 1.00 | AKR1C3 (0.65) | AKR1C3ALDH1A1MEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL28164225 | 0.98 | AKR1C3 (0.62) | AKR1C3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL12069685 | 0.88 | AKR1C3 (0.54) | AKR1C3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL9093746 | 0.87 | LMNA (0.71) | ALDH1A1MEN1KMT2AMAPTHTT | |
| SCHEMBL6065393 | 0.85 | KDM4E (0.80) | AKR1C3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL12592305 | 0.85 | KDM4E (0.55) | AKR1C3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL10373626 | 0.85 | MAPT (0.77) | AKR1C3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4873317 | 0.82 | NPC1 (0.62) | AKR1C3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL14746247 | 0.81 | KDM4E (0.48) | AKR1C3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4922234 | 0.81 | MAPT (0.73) | AKR1C3ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105837526-B | A kind of preparation method of the alcohol of 4 benzyl 3 (4 fluorophenyl) morpholine of the important synthetic intermediate of aprepitant (2S, 3R) 2 | 浙江工业大学 | 2018-02-27 | — | — | CN | claimed |
| CN-1147254-A | Prodrugs of morpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 1997-04-09 | — | — | CN | claimed |
| CN-111943904-B | Refining method of key intermediate of neurokinin 1 receptor antagonist | 南京正大天晴制药有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-112262128-A | Method for forming aryl carbon-nitrogen bond by illumination and photoreactor for carrying out the reaction | 科罗拉多州立大学研究基金会 | 2021-01-22 | — | — | CN | disclosed |
| US-20200147581-A1 | METHODS FOR FORMING ARYL CARBON-NITROGEN BONDS USING LIGHT AND PHOTOREACTORS USEFUL FOR CONDUCTING SUCH REACTIONS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200147581-A1 | METHODS FOR FORMING ARYL CARBON-NITROGEN BONDS USING LIGHT AND PHOTOREACTORS USEFUL FOR CONDUCTING SUCH REACTIONS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-05-14 | — | — | US | disclosed |
| US-20190345122-A1 | METHODS FOR FORMING ARYL CARBON-NITROGEN BONDS USING LIGHT AND PHOTOREACTORS USEFUL FOR CONDUCTING SUCH REACTIONS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2019-11-14 | — | — | US | disclosed |
| US-20190345122-A1 | METHODS FOR FORMING ARYL CARBON-NITROGEN BONDS USING LIGHT AND PHOTOREACTORS USEFUL FOR CONDUCTING SUCH REACTIONS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2019-11-14 | — | — | US | disclosed |
| EP-3197893-B1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-10-24 | — | — | EP | disclosed |
| CN-104650143-B | The method for preparing fosaprepitant dimeglumine intermediate | 山东新时代药业有限公司 | 2018-10-02 | — | — | CN | disclosed |
| US-10000489-B2 | Compounds αvβ6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| CN-1067683-C | Substituted morpholine derivatives and their use as therapeutic agents | MERK SHARP & DOHME LTD (GB) | 2001-06-27 | — | — | CN | disclosed |
| CN-1049431-C | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 2000-02-16 | — | — | CN | disclosed |
| US-5773437-A | UROGENITAL DISORDERS SUCH AS DYSURIA | NIPPON CHEMIPHAR CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| EP-0778831-A1 | MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1997-06-18 | — | — | EP | disclosed |
| CN-1147254-A | Prodrugs of morpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 1997-04-09 | — | — | CN | disclosed |
| CN-1139927-A | Substituted morpholine derivatives and their use as therapeutic agents | MERK SHARP & DOHME LTD (GB) | 1997-01-08 | — | — | CN | disclosed |
| EP-0748320-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-12-18 | — | — | EP | disclosed |
| EP-0734381-A1 | MORPHOLINE AND THIOMORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-10-02 | — | — | EP | disclosed |
| WO-1996007649-A1 | MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000489-B2 | Compounds αvβ6 integrin antagonists | ITGB6, ITGAV, ITGA6 | AKR1C3 4459/4885ALDH1A1 1818/4885MEN1 3322/4885 |
| US-20190345122-A1 | METHODS FOR FORMING ARYL CARBON-NITROGEN BONDS USING LIGHT AND PHOTOREACTORS USEFUL FOR CONDUCTING SUCH REACTIONS | TYR, CRY2, CRY1 | AKR1C3 647/4885ALDH1A1 1574/4885MEN1 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.